An unnamed 79-year-old man had quietly received special access to the most powerful experimental obesity drug currently in clinical trials. The clinician who requested it worked at the National Institutes of Health. The drug company that approved it – Eli Lilly – has a documented relationship with the president. And when reporters asked the White House whether the patient was Donald Trump, nobody said no for hours. That initial silence is what kept this story alive well past the moment a single sentence could have ended it.
The White House did eventually deny it. But the denial came loudly, aggressively, and more than a day after the question was first asked – and it arrived not as a calm factual correction but as a public attack on the reporter who wrote it. Which, as communications strategies go, had roughly the opposite of its intended effect.
What the whole episode confirmed, regardless of who that 79-year-old patient actually is, is that retatrutide – a still-unapproved Trump obesity drug candidate from Eli Lilly – has become one of the most politically and medically significant drugs in development. And the circumstances of how one anonymous person apparently got access to it before anyone else tells you a lot about who this story is really about.
Who Is This Patient, and Why Does It Look Like Trump?
The details of the compassionate use application, first reported by STAT News, are specific enough that they point in a narrow direction. The patient was a 79-year-old man, at the time the request was made in April, seeking treatment for refractory obesity – a severe form of the condition defined as the failure to achieve and maintain at least 5 percent weight loss over a six-month period, despite using five or more medical therapies at their maximum tolerated dosages. He also had obstructive sleep apnea and pulmonary hypertension, which is elevated blood pressure in the arteries that supply the lungs and can lead to heart failure if untreated. The NIH’s senior clinician Ranganath Muniyappa made the request and reportedly recommended against bariatric surgery because of the patient’s age and medical conditions.
The patient had previously been on tirzepatide – the active ingredient in Zepbound and Mounjaro, both FDA-approved Eli Lilly drugs – for at least a year but achieved only moderate weight loss. A physician then reached for something still in Phase 3 trials. Three sources familiar with the matter told STAT that the case drew the interest of top health officials, suggesting the person receiving the drug was “well connected.”
Trump weighs 224 pounds according to his most recent physical, and in a January interview he told reporters that while he hadn’t taken Ozempic or Wegovy, he admitted he “probably should.” His most recent annual medical exam found his BMI close to the threshold for clinical obesity, with his doctor recommending more exercise and a reduction in his daily aspirin intake. He also turned 80 in June 2026 – meaning the April request, when the patient was 79, fits his timeline precisely.
There’s also a corporate dimension. Eli Lilly CEO David Ricks attended a dinner at Trump’s Mar-a-Lago residence alongside other pharmaceutical executives, and Trump has publicly praised Ricks as an “unbelievable executive.” Experts who follow obesity medicine were surprised that Eli Lilly approved access to retatrutide for a single patient outside of any clinical trial. Usually, when companies engage with the compassionate use pathway, they do so for a larger cohort. “If you really were trying to treat obesity in people who can’t use the products that are out there, why would you go the single patient route?” NYU health ethicist Alison Bateman-House put it bluntly. One patient, one approved exception, for a drug that millions are waiting for.
What Is Retatrutide, and Why Is It Such a Big Deal?
Retatrutide is not Ozempic with a different name. It’s a significant step forward from the GLP-1 drugs – like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) – that have already reshaped conversations about obesity treatment. Retatrutide is an investigational once-weekly triple hormone receptor agonist, meaning it’s a single molecule that activates the body’s receptors for three separate hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. GLP-1 drugs like Ozempic act on one of those three pathways. Tirzepatide hits two. Retatrutide hits all three simultaneously, which is why researchers have been calling it a “triple agonist” and why its trial results have genuinely surprised people who thought weight-loss pharmacology had already peaked.
According to May 2026 results, the highest dose helped patients lose an average of 28.3% of their body weight – about 70 pounds – over 80 weeks, compared with 2.2% with placebo, among patients who stayed on the drug. Roughly 45% of the 2,500 patients in the Phase 3 trial achieved 30% or more weight loss. To put that in context: most obesity medications available a decade ago were considered effective if they produced 5 to 10 percent weight loss. Retatrutide, at its highest dose, is producing results that rival bariatric surgery.
Eli Lilly is studying retatrutide in several Phase 3 clinical trials covering obesity, overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic liver disease. Severe obesity touches almost every system in the body, which is why a drug that effectively addresses it can have cascading effects across a patient’s other conditions. Obstructive sleep apnea and pulmonary hypertension – two of the conditions cited in the compassionate use application – are both on that list.
Retatrutide was associated with the gastrointestinal side effects typical of this class of drugs: nausea, diarrhea, constipation, vomiting, and decreased appetite, all occurring more frequently than with placebo. The drug is not yet FDA-approved, and the full safety profile is still being established. The compassionate use pathway exists precisely for situations where the potential benefit is judged to outweigh the still-uncertain risk, which is why the conditions for qualifying are stringent.
How the Compassionate Use Program Actually Works
The “compassionate use” program sounds informal, almost like a special favor. It isn’t. According to the FDA, compassionate use – formally called expanded access – is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Getting access requires agreement from three separate parties: the physician, the pharmaceutical manufacturer, and the FDA itself. Even if a patient meets the criteria, the licensed physician, the IRB (Institutional Review Board, an independent ethics committee that oversees research involving human subjects), or the company may still refuse. The physician must determine that the possible risks from the investigational product are not greater than the possible risks from the disease itself.
The bar is high on purpose. Granting a single person access to a drug that hasn’t finished clinical trials means accepting real unknowns about safety. All compassionate use patients must have exhausted all approved treatment options, be ineligible for any ongoing clinical trials, and have no comparable or alternate treatment available. This isn’t a shortcut. It’s a last resort – on paper.
The fact that retatrutide was granted through this channel to one patient is what made physicians and experts in obesity treatment take notice. The drug is still deep in Phase 3 trials. Lilly has not filed for FDA approval. And yet, in at least one case, the company agreed to provide it outside of any clinical setting – something it rarely does for a drug at this stage.
The White House Response Didn’t Help Its Own Case
A White House spokesperson reacted sharply after he was quoted failing to deny the report. White House spokesperson Kush Desai publicly lashed out at STAT’s reporter Lizzy Lawrence, who had noted in her original report that Desai had not explicitly denied that Trump was the patient in question.
Desai wrote on X: “Because this has to be spelled out for @LizzyLaw, who has proven herself to be an unserious gossip columnist, this application was not for the President.” Hours after that, White House Communications Director Steven Cheung added his own attack, calling Lawrence a “big idiot” who had “completely embarrassed” herself. Lawrence responded on X that she had asked Desai, the FDA, and HHS “multiple times” on Monday whether the application was for Trump. “No one answered my question directly,” she wrote.
The aggressive personal attacks on the reporter, rather than a simple and immediate factual denial, kept the story in the news cycle for another 24 hours. The White House’s own communications strategy amplified a story it claimed was baseless. HHS was similarly evasive when STAT first reached out, never directly denying the theory in its initial response.
Trump and Weight-Loss Drugs: Not a New Conversation
Whatever the truth of the retatrutide report, the president’s interest in weight-loss drugs is not a new or secret thing. Throughout his second term, Trump has expressed a keen interest in weight-loss drugs and directed his administration to lower their costs. In April 2025, Health Secretary Robert F. Kennedy Jr. told CBS Mornings that Trump had “ordered” his department to bring the costs of GLP-1 drugs down in the U.S. to compete with European prices.
In November 2025, Trump announced that the prescription costs of Ozempic and Wegovy would come down by hundreds of dollars if purchased through his discounted prescription drug marketplace, TrumpRx. Trump has even used his own officials as props in the effort. During the White House event unveiling the TrumpRx arrangement, he asked his assembled cabinet members to identify who among them was already taking the drugs – publicly outing his communications director Steven Cheung as a GLP-1 user in the process.
Trump has had multiple medical physicals since returning to office. After his evaluation in May – his third in 13 months – the White House said he “remains in excellent health” but was advised to lose weight and exercise more. That language, buried in an otherwise upbeat press release, is not nothing. Being advised by your physician to lose weight while simultaneously presiding over a White House rollout of discounted GLP-1 drugs creates a context that is hard to set aside when a report surfaces about a 79-year-old man getting experimental access to the most powerful obesity drug currently in development.
Read More: If You Struggled to Lose Weight as a Child, You Probably Display these 25 Habits Now
What We Actually Know
The honest answer, as of now, is that nobody outside the relevant medical teams knows who that patient is. The White House says it wasn’t Trump. STAT News says it was reporting what its sources told it, asked the right questions, and got no straight answer until after the story ran. Both things can be true and still leave us in the same place: a period of initial silence from the people who could have killed this story in 30 seconds with a direct denial.
What the episode does confirm, regardless of who the patient is, is that retatrutide is serious medicine. An NIH clinician thought it was the right call for a patient with obstructive sleep apnea and pulmonary hypertension who hadn’t responded adequately to Zepbound. Eli Lilly agreed to provide it outside of a clinical trial. The FDA approved the compassionate use request. That chain of medical decisions, not the political drama around it, is what will matter five years from now, when retatrutide is likely on pharmacy shelves and the specifics of this particular controversy have faded.
The deeper question, one that a lot of people with serious obesity and its related conditions are sitting with right now, is about access. If this drug works as well as the Phase 3 data suggests – 70 pounds lost, results comparable to surgery – then getting it will matter enormously to millions of people who are not the boss of the regulatory agency that approved it. The politics of weight-loss drugs in 2026 – who promotes them, who can afford them, who gets them first – is a story that runs much further than any single patient’s medical file. And it’s one that isn’t going away.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.